Malondialdehyde as a candidate biomarker for bipolar disorder: A meta-analysis.

Autor: Capuzzi E; Psychiatric Department, Azienda Socio Sanitaria Territoriale Monza, Monza, Italy. Electronic address: e.capuzzi1@campus.unimib.it., Ossola P; Department of Medicine and Surgery, University of Parma, Parma, Italy., Caldiroli A; Psychiatric Department, Azienda Socio Sanitaria Territoriale Monza, Monza, Italy., Auxilia AM; Department of Medicine and Surgery, University of Milano Bicocca, via Cadore 38, 20900 Monza, MB, Italy., Buoli M; Department of Neurosciences and Mental Health, Fondazione IRCCS Ca'Granda Ospedale, Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Jazyk: angličtina
Zdroj: Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2022 Mar 08; Vol. 113, pp. 110469. Date of Electronic Publication: 2021 Nov 02.
DOI: 10.1016/j.pnpbp.2021.110469
Abstrakt: Malondialdehyde (MDA) represents one of the final products of lipid peroxidation that is thought to be enhanced and accelerated in patients affected by bipolar disorder (BD). Purpose of the present article is to critically summarize the available data about MDA as a candidate biomarker for BD. First, we carried out a systematic review of the literature selecting those papers that evaluated MDA levels in BD. Then, we performed two separate meta-analyses: one of the studies that compared healthy controls (HC) with unmedicated BD and one with the studies that assessed MDA levels before and after treatment in BD, showing that bipolar patients experience more oxidative stress than healthy subjects and that treatment is effective in reducing MDA levels. In the first set of studies, we also explored through a meta-regression whether age, gender and experiencing an episode specifically influenced the difference between BD and HC in MDA levels. Bipolar patients compared to healthy subjects had higher MDA levels (SMD: 0.94, 95% CI: 0.23-1.64). Age (p < 0.01), gender (p < 0.01) and the presence of a current mood episode (p < 0.01) significantly influenced MDA plasma/serum levels. Specifically, studies that included more female, older subjects and more BD in euthymia were more likely to have higher MDA levels. Finally, patients after treatment had lower levels of MDA compared to baseline (SMD: -0.52, 95% CI: -0.85 -0.19). More studies are needed to draw definitive conclusions.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: